Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers

Current Medicinal Chemistry

Volumn 19, Issue 20, 2012, Pages 3301-3309

  Tateishi, U ^a   Oka, T ^a   Inoue, T ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Integrin; Integrin alpha(v)beta3; PET; PET CT; Positron emission tomography; Radiolabeled RGD; RGD; RGD peptide; VEGF

Indexed keywords

7 AMINO LYERO GALACTO 2,6 ANHYDRO 7 DEOXYHEPTANAMIDE F 18; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CILENGITIDE; ETARACIZUMAB; FLUCICLATIDE F 18; N (2 AMINOETHYL)MALEIMIDE F 18; N [2 (4 FLUOROBENZAMIDO)ETHYL]MALEIMIDE F 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

BINDING AFFINITY; CARCINOGENESIS; CELL MEMBRANE; DISEASE MARKER; GLYCOSYLATION; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CELL LINE, TUMOR; HUMANS; INTEGRIN ALPHAVBETA3; ISOTOPE LABELING; NEOPLASMS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

EID: 84863743045     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801215937     Document Type: Review

References (105)

1. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
2. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lesions and opportunities. Nat Rev Drug Discov. 2010;9:804-820.
3. Cabodi S, Di Stefano P, Leal Mdel P, Tinnirello A, Bisaro B, Morello V, Damiano L, Aramu S, Repetto D, Tornillo G, Defilippi P. Integrins and signal transduction. Adv Exp Med Biol. 2010;674:43-54.
4. White DJ, Puranen S, Johnson MS, Heino J. The collagen receptor sub family of the integrins. Int J Biochem Cell Biol. 2004;36:1405-1410.
5. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev. 2008;27:631-644.
6. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET Imaging of Integrin ctVß3 Expression. Theranostics. 2011;1:48-57.
7. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, Gambhir SS, Chen X. microPET imaging of glioma integrin (alpha)v(beta)3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-1718.
8. Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, Bremner R, Bading JR, Conti PS. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
9. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002;8:918-921.
10. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci. 2009;14:887-899.
11. Haubner R, Decristoforo C. Radiolabeled RGD peptides and peptidomimetics for tumour targeting. Front Biosci. 2009;14:872-886.
12. Rice SL, Roney CA, Daumar P, Lewis JS. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med. 2011;41:265-282.
13. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10:753-768.
14. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
15. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007;18:1400-1407.
16. Tateishi U, Kusumoo M, Nishihara H, Nagashima K, Morikawa T, Moriyama N. Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer. 2002;95:835-842.
17. Beer AJ, Schwaiger M. PET imaging of avß3 expression in cancer patients. Methods Mol Biol. 2011;680:183-200.
18. Decristoforo C, Hernandez Gonzalez I, Carlsen J, Rupprich M, Huisman M, Virgolini I, Wester HJ, Haubner R. 68Ga-and 111In-labeled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2008;35:1507-1515.
19. Johanna Haukkala, Iina Laitinen, Pauliina Luoto, Peter Iveson, Ian Wilson, Hege Karlsen, Alan Cuthbertson, Jukka Laine, Pia Leppänen, Ylä-Herttula S, Knuuti J, Roivainen A. 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging. 2009;36:2058-2067.
20. Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging. 2008;35:1100-1108.
21. Dijkgraaf I, Yim CB, Franssen GM, Schuit RC, Luurtsema G, Liu S, Oyen WJ, Boerman OC. PET imaging of ccvß3 integrin expression in tumours with Ga-labeled mono-, di-and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging. 2011;38:128-137.
22. Donnelly PS, Ma MT, Neels O, Denoyer D, Roselt P, Karas J, Scanlon D, White JM, Hicks R. Tumor imaging with a gallium-68 complex of a macrobicyclic cage amine ligand tethered to two integrin-targeting peptides. Bioconjug Chem. 2011Aug 31. [Epub ahead of print].
23. Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M. Novel (64)Cu-and (68)Ga-labeled RGD conjugates show improved PET imaging of a(v)ß(3) integrin expression and facile radiosynthesis. J Nucl Med. 2011;52:1276-1284.
24. Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ, Lee DS, Chung JK, Lee MC. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid and feasibility studies in mice. J Nucl Med. 2008;49:830-836.
25. Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, von Guggenberg E, Pichler BJ, Virgolini I, Decristoforo C, Haubner R. [68Ga]NODAGA-RGD for imaging ctvß3 integrin expression. Eur J Nucl Med Mol Imaging. 2011;38:1303-1312.
26. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
27. Li ZB, Wu Z, Chen K, Chin FT, Chen X. Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem. 2007;18:1987-1994.
28. Liu S, Liu H, Jiang H, Xu Y, Zhang H, Cheng Z. One-step radiosynthesis of 18F-AlF-NOTA-RGD 2 for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging.2011;38:1732-1741.
29. Selvaraj R, Liu S, Hassink M, Huang CW, Yap LP, Park R, Fox JM, Li Z, Conti PS. Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin a(v)ß(3) targeted PET tracer based on a cyclic RGD peptide. Bioorg Med Chem Lett. 2011;21:5011-5014.
30. Namavari M, Cheng Z, Zhang R, De A, Levi J, Hoerner JK, Yaghoubi SS, Syud FA, Gambhir SS. A novel method for direct site-specific radiolabeling of peptides using [18F]FDG. Bioconjug Chem. 2009;20:432-436.
31. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Bading JR, Laug WE, Conti PS. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging. 2004;31:1081-1089.
32. Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, Bremner R, Bading JR, Conti PS. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
33. Liu S, Liu Z, Chen K, Yan Y, Watzlowik P, Wester H J, Chin FT, Chen X. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of ctvß3 integrin expression. Mol Imaging Biol. 2010;12:530-538.
34. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm. 2006;3:472-487.
35. Wängler C, Maschauer S, Prante O, Schäfer M, Schirrmacher R, Bartenstein P, Eisenhut M, Wängler B. Multimerization of cRGD peptides by click chemistry: synthetic strategies, chemical limitations, and influence on biological properties. Chembiochem. 2010;11:2168-2181.
36. Ogawa M, Hatano K, Oishi S, Kawasumi Y, Fujii N, Kawaguchi M, Doi R, Imamura M, Yamamoto M, Ajito K, Mukai T, Saji H, Ito K. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging. Nucl Med Biol. 2003;30:1-9.
37. Janssen M, Oyen WJ, Massager LF, Frielink C, Dijkgraaf I, Edwards DS, Corstens FH, Boerman OC. Comparison of a monomeric and dimeric radiolabeled RGD-pepitide for tumor targeting. Cancer Biother Radiopharm 2002;17:641-646.
38. Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R, Henriksen G, Kessler H, Schwaiger M, Wester HJ. Chemoselective pre-conjugate radiohalogenation of upprotected mono-and multimeric peptides via oxime formation. Radiochemica Acta 2004;92:317-327.
39. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, Chen X. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med. 2007;48:1162-1171.
40. Wu Z, Li ZB, Cai W, He L, Chin FT, Li F, Chen X. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2007;34:1823-1831.
41. Wu Z, Li ZB, Cai W, He L, Chin FT, Chen X. (18)F-labeled mini-PEG spacered RGD dimer ((18)F-FPRGD2): synthesis and microPET imaging of alphavbeta 3 integrin expression. Eur J Nucl Med Mol Imaging 2007;34:1823-1931.
42. Wu Z, Li ZB, Chen K, Cai W, He L, Chin FT, Chen X. MicroPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 2007;48:1536-1544.
43. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, Conti PS. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004;6:350-359.
44. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, Chen X. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med. 2007;48:1162-1171.
45. Liu Z, Yan Y, Chin FT, Wang F, Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem. 2009;52:425-432.
46. Reubi JC, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumor imaging. Fur J Nucl Med Mol Imaging. 2002;29:855-862.
47. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793.
48. de Jong M, Bernard BF, Breeman WA, Srinivasan A, Schmidt MA, Krenning EP, van Hagen M. Radiolabeled cyclic RGD-DTPA-octreotate analog for tumor imaging and radionuclide therapy. J Nucl Med. 2001;42:111P (Suppl).
49. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Sceel-Toellner D, Simmons DL, Akbar AN, Lord JM, Salmon M. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 1999;397;534-539.
50. Bernard BF, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M. Radilabeled RGD-DTPA-Thr3 octreptate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm. 2004;45:1716-1720.
51. Capello A, Krenning EP, Bermard BF, Breeman WA, van Hagen MP, de Jong M. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med. 2004;45:1716-1720.
52. Jacobson O, Zhu L, Niu G, Weiss ID, Szajek LP, Ma Y, Sun X, Yan Y, Kiesewetter DO, Liu S, Chen X. MicroPET Imaging of Integrin ct(v)ß (3) Expressing tumors using (89)Zr-RGD Peptides. Mol Imaging Biol. 2010 Dec 16. [Epub ahead of print].
53. Dredge K, Dalgleish AG, Marriott JB. Recent developments in antiangiogeneic therapy. Expert Opin Biol Ther. 2002;2:953-966.
54. Sulyok GA, Gibson C, Goodman SL, Holzemann G, Wiesner M, Kessler H. Solid-phase synthesis of a nonpeptide RGD mimeric library: new selective alphavbeta3 integrin antagonists J Med Chem. 2001;44:1938-1950.
55. Haubner R, Thumshirn G, Weber WA, Herz M, Wester HJ, Kessler H, Schwaiger M. [F-18]GBHO-2: a RGD-mimeric for the non-invasive determination of the alpha(v)beta3 expression. Nuclear Medicine. 2003;42:45.
56. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
57. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
58. Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005;41:1291-9.
59. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
60. Cao Q, Li ZB, Chen K, Wu Z, He L, Neamati N, Chen X. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging. 2008;35:1489-1498.
61. Jacobson O, Zhu L, Ma Y, Weiss ID, Sun X, Niu G, Kiesewetter DO, Chen X. Rapid and simple one-step F-18 labeling of peptides. Bioconjug Chem. 2011;22:422-428.
62. Chin FT, Shen B, Liu S, Berganos RA, Chang E, Mittra E, Chen X, Gambhir SS. First Experience with Clinical-Grade [(18)F]FPP(RGD) (2): An automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol. 2011 Mar 12. [Epub ahead of print].
63. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptides and positron emission tomography. Cancer Res. 2001;61:1781-1785.
64. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M. Mominvasive visualization of the activated alphavbeta3 integrin in cancer patients by positrom emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70
65. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, Kessler H, Schwaiger M, Wester HJ. Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892-902.
66. Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R, Henriksen G, Kessler H, Schwaiger M, Wester HJ. Chemoselective pre-conjugate radiohalogenation of unprotected mono-and multimeric peptides via oxime formation. Radiochemica Acta. 2004;92:317-327.
67. Schirrmacher E, Wangler B, Crpryk M, Bradtmoller G, Schafer M, Eisenhut M, Jurchat K, Schirrmacher R. Synthesis of p-(Di-tert-butyl[18F]fluorosilyl) benzaldehyde ([18F]SiFA-A) with high specific activity by isotopic exchange: a convenient labeling synthon for the 18F-labeling of N-amino-oxy derivatized peptides. Bioconjug Chem. 2007;18:2085-2089.
68. Prante O, Einsiedel J, Haubner R, Gmeiner P, Wester HJ, Kuwert T, Maschauer S. 3, 4, 6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl phenylthiosulfonate: a thiol-reactive agent for the chemoselective 18F-glycosylation of peptides. Bioconjug Chem. 2007;18:254-262.
69. Cai w, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med. 2006;47:1172-1180.
70. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
71. Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, Grosu AL, Martinez MJ, Wester HJ, Weber WA, Schwaiger M. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med. 2006;47:763-769.
72. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F, Schwaiger M. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22-29.
73. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
74. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70.
75. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610-6616.
76. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
77. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Pöpperl G, Holtmannspötter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M, Beer AJ. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol. 2009;11:861-870.
78. Chen X, Park R, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Moats RA, Bading JR, Laug WE, Conti PS. Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. Mol Imaging Biol. 2006;8:9-15.
79. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Bading JR, Laug WE, Conti PS. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging. 2004;31:1081-1089.
80. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M. Patterns of alphavbeta3 expression in primary andmetastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008;49:255-259.
81. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, Chen X. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med. 2006;47:113-121.
82. Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH, Bading JR, Moats R, Laug WE, Conti PS. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
83. Ferl GZ, Dumont RA, Hildebrandt IJ, Armijo A, Haubner R, Reischl G, Su H, Weber WA, Huang SC. Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J Nucl Med. 2009;50:250-258.
84. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F-and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41-49.
85. Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med. 2004;45:1776-1783.
86. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, Conti PS. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6:350-359.
87. Wu Y, Zhang X, Xiong Z. MicroPET imaging of glioma integrin {alpha}v{beta}3 expression using 64Cu-labeled dimeric RGD peptide. J Nucl Med 2005;46:1707-1718.
88. Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M. Novel (64)Cu-and (68)Ga-labeled RGD conjugates show improved PET imaging of a(v)ß(3) integrin expression and facile radiosynthesis. J Nucl Med. 2011;52:1276-1284.
89. Jin ZH, Furukawa T, Galibert M, Boturyn D, Coll JL, Fukumura T, Saga T, Dumy P, Fujibayashi Y Noninvasive visualization and quantification of tumor ctVß3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4. Nucl Med Biol. 2011;38:529-540.
90. Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Achilefu S, Anderson CJ. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl Med Biol. 2009;36:277-285.
91. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrinaVß3. Cancer Res. 2006;66:9673-9681.
92. Tomasi G, Kenny L, Mauri F, Turkheimer F, Aboagye EO. Quantification of receptor-ligand binding with [(18)F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging. 2011 Sep 3. [Epub ahead of print]
93. Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled aVbeta3-integrin and aV beta5-integrin imaging agent. J Nucl Med. 2011;52:424-430.
94. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
95. Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med. 2009;50:116-122.
96. Choyke PL. Pilot study of FPPRGD2 for imaging a(v)ß(3) integrin-how integral are integrins? Radiology. 2011;260:1-2.
97. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging a(v)ß(3) integrin levels. Radiology. 2011;260:182-191.
98. Chang E, Liu S, Gowrishankar G, Yaghoubi S, Wedgeworth JP, Chin F, Berndorff D, Gekeler V, Gambhir SS, Cheng Z. Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts. Eur J Nucl Med Mol Imaging. 2011;38:722-730.
99. Wu Z, Li ZB, Cai W, He L, Chin FT, Li F, Chen X. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2007;34:1823-1831.
100. Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging. 2009;36:1296-1307.
101. Chin FT, Shen B, Liu S, Berganos RA, Chang E, Mittra E, Chen X, Gambhir SS. First experience with clinical-grade [(18)F]FPP(RGD) (2): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol. 2011 Mar 12. [Epub ahead of print]
102. Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, Shen B, Niu G, Chen X. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 2011;52:140-146.
103. Wu Z, Li ZB, Chen K, Cai W, He L, Chin FT, Li F, Chen X. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med. 2007;48:1536-1544.
104. Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med. 2006;47:1172-1180.
105. Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res. 2007;67:7833-7840.